In addition, GCSH expression is clearly lowered with increasing glioma grade, while that of PLEK2 and RRM2 is clearly elevated; therefore, GCSH does not fit the premise of targeted therapy, i.e., biological pathway inhibition [68]. This evidence concerns the gene RRM2 and central nervous system cancer.